Challenging tumor resistance with less toxic, more effective drug combinations: an example from neuroblastoma

Cell Death Dis. 2018 Jun 7;9(6):686. doi: 10.1038/s41419-018-0728-1.

Authors

Alessandra Gambacurta¹, Giuseppe Raschellà²

Affiliations

¹ Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy. gambacur@uniroma2.it.
² ENEA Research Center Casaccia, Laboratory of Biosafety and Risk Assessment, Via Anguillarese, 301, 00123, Rome, Italy. giuseppe.raschella@enea.it.

No abstract available

Publication types

News

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cell Cycle / drug effects
Cell Death / drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm* / drug effects
Humans
Neuroblastoma / drug therapy*
Neuroblastoma / pathology
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors